| 
Fusion
/ Entry Inhibitors
FUZEON
Drug Summary Page
(enfuvirtide; T-20)
CCR5 Co-receptor / Entry Inhibitor -
Aplaviroc (APL. 873140)
-
Vicriviroc
- Maraviroc
(UK-427,857)
CXCR4 Co-receptor / Entry
Inhibitor
Articles
on Fusion / Entry Inhibitors
Two
Novel Fusion Inhibitors Demonstrate In Vitro Activity against HIV
-
8/29/06
Safety
and Efficacy of Maraviroc, a CCR5 Antagonist, for the Treatment
of Treatment-experienced Patients Infected with Dual/Mixed-tropic HIV - 8/18/06
A
Phase II Study of the Safety and Efficacy of the CCR5 Antagonist Vicriviroc
- 8/18/06
New
Insights on Use by AIDS Patients of Pfizer’s Experimental CCR5 Antagonist Maraviroc
- 8/15/06
Towards Gene Knock Out Therapy for AIDS/HIV:
Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases
(ZFNs). Y Jouvenot and others. -
12/18/05
The Pharmacokinetic Interaction Between
the Entry Inhibitor Aplaviroc (APL, 873140) and Efavirenz in Healthy
Adults. K Adkinson and others. -
12/18/05
Absence of Pharmacokinetic (PK) Drug Interaction
Between Aplaviroc (APL, 873140) and Tenofovir Disoproxil Fumarate (TDF).
I Song and others. -
12/18/05
Analysis of In Vitro-Derived Viruses Exhibiting
Reduced Susceptibility to Aplaviroc. C Labranche and others. -
12/18/05
Co-administration of Fosamprenavir/Ritonavir
Overcomes the Effect of Efavirenz Induction on Aplaviroc (APL; 873140) Pharmacokinetics.
K Adkinson and others. -
12/18/05
Minimal to No Changes in Plasma Chemokine/Cytokine
Levels in HIV-Negative and HIV-Positive Subjects Following Short Term Administration
of Aplaviroc K Kitrinos and others.
Emerging
Populations of Enfuvirtide Resistant HIV-1 Contain Multiple Variants that
Compete for Dominance
- 6/27/05
T-1249
Retains Potent Antiretroviral Activity in Patients with Virological Failure While
on Enfuvirtide-containing Regimen - 3/14/05
New
Entry Inhibitor AMD-070 Shows Promise in Early Human Testing - 1/03/05
Roche
and Trimeris Will Provide 60 Days Free Access to Fuzeon for Qualified Patients
- 06/13/04
Enter
the Entry Inhibitors -
07/23/04
| 
